Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Dow Gains 100 Points; Chicago PMI Falls In August - Quoin Pharmaceuticals (NASDAQ:QNRX), Antelope Enterpr